Substrate Guided Ablation Therapy for Atrial Fibrillation
Launched by ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST · Dec 6, 2020
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
This is a single-centre, non-randomized study investigating the feasibility, safety and efficacy of substrate guided ablation in persistent AF.
The study population will be patients between the ages of 18 and 80 with symptomatic, persistent atrial fibrillation (≥1 year) referred for catheter ablation on standard clinical grounds.
The catheter ablation procedure will be performed using the Precision Ensite™ three dimensional mapping system and the Advisor High Density Grid™ mapping catheter (Abbott Medical Incorporated). All patients will undergo conventional pulmonary vein isolation (PVI)...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged ≥18 years and ≤ 80 with a clinical indication for persistent atrial fibrillation ablation
- Exclusion Criteria:
- • Contraindication to anticoagulation
- • Thrombus in the left atrium despite anticoagulation
- • Cerebrovascular accident within the previous 6 months
- • Patients actively participating in another research study will be not be permitted to enrol. Patients who have been involved with other research studies will be able to participate after a minimum period of 3 months after completion of prior study follow up
- • Females of childbearing potential must have a negative pregnancy test on the day of the ablation procedure due to the radiation exposure during the procedure
About Royal Brompton & Harefield Nhs Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust is a leading specialist healthcare provider in the United Kingdom, renowned for its expertise in cardiothoracic medicine and respiratory care. Committed to advancing clinical research and improving patient outcomes, the Trust conducts a diverse range of clinical trials aimed at exploring innovative treatments and therapies. With a multidisciplinary team of clinicians and researchers, the Foundation Trust fosters a collaborative environment that prioritizes patient safety and ethical standards, contributing significantly to the global body of medical knowledge and enhancing the quality of care for patients with complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Shouvik Haldar, FRCP MD
Principal Investigator
Royal Brompton and Harefield Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials